Nanjing School of Clinical Medicine, Southern Medical University, Jinling Hospital, Nanjing, 210002, People's Republic of China.
Institute of Biotherapy, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Int J Biol Sci. 2019 Sep 7;15(11):2381-2392. doi: 10.7150/ijbs.35980. eCollection 2019.
Lung cancer is a malignancy with high morbidity and mortality worldwide. More evidences indicated that gut microbiome plays an important role in the carcinogenesis and progression of cancers by metabolism, inflammation and immune response. However, the study about the characterizations of gut microbiome in lung cancer is limited. In this study, the fecal samples were collected from 16 healthy individuals and 30 lung cancer patients who were divided into 3 groups based on different tumor biomarkers (cytokeratin 19 fragment, neuron specific enolase and carcinoembryonic antigen, respectively) and were analyzed using 16S rRNA gene amplicon sequencing. Each lung cancer group has characterized gut microbial community and presents an elimination, low-density, and loss of bacterial diversity microbial ecosystem compared to that of the healthy control. The microbiome structures in family and genera levels are more complex and significantly varied from each group presenting more different and special pathogen microbiome such as aceae, , a, and fewer probiotic genera including and . The Kyoto Encyclopedia of Genes and Genomes (KEGG) and COG annotation demonstrated decreased abundance of some dominant metabolism-related pathways in the lung cancer. This study explores for the first time the features of gut microbiome in lung cancer patients and may provide new insight into the pathogenesis of lung cancer system, with the implication that gut microbiota may serve as a microbial marker and contribute to the derived metabolites, development and differentiation in lung cancer system.
肺癌是一种具有高发病率和死亡率的恶性肿瘤。越来越多的证据表明,肠道微生物群通过代谢、炎症和免疫反应在癌症的发生和进展中发挥重要作用。然而,关于肺癌肠道微生物群特征的研究还很有限。在这项研究中,从 16 名健康个体和 30 名肺癌患者中收集了粪便样本,这些患者根据不同的肿瘤生物标志物(细胞角蛋白 19 片段、神经元特异性烯醇化酶和癌胚抗原)分为 3 组,并通过 16S rRNA 基因扩增子测序进行分析。每个肺癌组都具有特征性的肠道微生物群落,并表现出与健康对照组相比,微生物多样性消除、低密度和丧失的微生物生态系统。在科和属水平上,微生物组结构更加复杂,各组之间的差异显著,表现出更多不同和特殊的病原体微生物组,如 Aceae、、A、和更少的益生菌属,包括和。京都基因与基因组百科全书(KEGG)和 COG 注释表明,肺癌中一些主要代谢相关途径的丰度降低。本研究首次探索了肺癌患者肠道微生物群的特征,可能为肺癌系统的发病机制提供新的见解,暗示肠道微生物群可能作为微生物标志物,并有助于肺癌系统中衍生代谢物的产生、发展和分化。
Int J Biol Sci. 2019-9-7
BMC Microbiol. 2022-2-25
J Multidiscip Healthc. 2025-7-29
Appl Microbiol Biotechnol. 2025-7-10
Biomedicines. 2025-5-25
Signal Transduct Target Ther. 2025-6-2
Microorganisms. 2025-4-29
Am Soc Clin Oncol Educ Book. 2019-1
Front Immunol. 2019-2-20
Cancers (Basel). 2019-1-3
Nat Microbiol. 2018-12-10